Blog
RSS FeedPosted by Michael Wonder on 15 Jul 2025
New cystic fibrosis drug fast tracked for NHS use
15 July 2025 - Some people with cystic fibrosis are set to benefit from a new once daily triple therapy treatment, ...
Posted by Michael Wonder on 12 Jun 2025
Gilead’s Trodelvy wins Korean coverage for breast cancer -- too late for some and still off-limits up front
12 June 2025 - It took two years, 100,000 signatures, and a wave of public pressure from patients and doctors. ...
Posted by Michael Wonder on 12 Jun 2025
Health Canada authorises PiaSky (crovalimab for injection) as the first monthly (every four weeks) subcutaneous treatment for people with paroxysmal nocturnal haemoglobinuria
11 June 2025 - Roche Canada is pleased to announce that Health Canada has authorised PiaSky (crovalimab for injection) as ...
Posted by Michael Wonder on 12 Jun 2025
Oxford vaccine against deadly Nipah virus granted EMA PRIME designation
11 June 2025 - The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from ...
Posted by Michael Wonder on 12 Jun 2025
Radiopharm Theranostics granted US FDA fast track designation for RAD101 imaging in brain metastases
11 June 2025 - Radiopharm Theranostics today announced that the US FDA has granted fast track designation for RAD101 to ...
Posted by Michael Wonder on 11 Jun 2025
Cantargia’s nadunolimab antibody awarded US FDA fast track designation
11 June 2025 - Cantargia today announced that the US FDA has granted fast track designation to nadunolimab, Cantargia's anti-IL1RAP antibody ...
Posted by Michael Wonder on 11 Jun 2025
FDA approves taletrectinib for ROS1 positive non-small cell lung cancer
11 June 2025 - Today, the FDA approved taletrectinib (Ibtrozi, Nuvation Bio), a kinase inhibitor, for adults with locally advanced ...
Posted by Michael Wonder on 11 Jun 2025
US FDA approves expanded indication for AbbVie's Mavyret (glecaprevir/pibrentasvir) as first and only treatment for people with acute hepatitis C virus
11 June 2025 - AbbVie today announced that the US FDA approved a label expansion for Mavyret (glecaprevir/pibrentasvir), an oral ...
Posted by Michael Wonder on 11 Jun 2025
Priorities for a new FDA
10 June 2025 - Why does it take more than 10 years for a new drug to come to market? Why ...
Posted by Michael Wonder on 11 Jun 2025
Calls for weight loss drugs like Ozempic to be subsidised for people with schizophrenia
11 June 2025 - Queensland researchers are calling for weight loss medicines to be listed on the PBS for people ...
Posted by Michael Wonder on 11 Jun 2025
Azurity Pharmaceuticals announces the FDA approval of Xifyrm (meloxicam injection) for the management of moderate to severe pain in adults
10 June 2025 - Azurity Pharmaceuticals today announced that the US FDA has approved Xifyrm (meloxicam injection), an intravenous non-steroidal ...
Posted by Michael Wonder on 10 Jun 2025
SNT-5505 awarded US FDA fast track designation
10 June 2025 - Syntara today announces that its lead candidate, SNT-5505, has been granted fast track designation by the ...
Posted by Michael Wonder on 10 Jun 2025
Zepzelca (lurbinectedin) and atezolizumab (Tecentriq) combination granted US FDA priority review for first-line maintenance treatment of extensive-stage small cell lung cancer
10 June 2025 - Target action (PDUFA) date set for 7 October 2025. ...
Posted by Michael Wonder on 10 Jun 2025
X4 Pharmaceuticals granted fast track designation for mavorixafor for the treatment of chronic neutropenia by US FDA
10 June 2025 - X4 Pharmaceuticals today announced that the US FDA has granted fast track designation to mavorixafor, an oral ...
Posted by Michael Wonder on 10 Jun 2025
Research funding and more treatment options to support the fight against MND
9 June 2025 - The Australian Government is providing a further $4.5 million and listing another treatment to ensure the ...
Posted by Michael Wonder on 10 Jun 2025
DoH publishes revised agenda for July 2025 PBAC meeting (version 4)
10 June 2025 - The DoH has published a revised agenda for next month's PBAC meeting. ...